Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Creelan BC, et al. Among authors: chiappori a. J Immunother. 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237. J Immunother. 2013. PMID: 23994887 Free PMC article. Clinical Trial.
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Fishman MN, et al. Among authors: chiappori aa. Clin Cancer Res. 2006 Jan 15;12(2):523-8. doi: 10.1158/1078-0432.CCR-05-0928. Clin Cancer Res. 2006. PMID: 16428495 Clinical Trial.
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Simon GR, et al. Among authors: chiappori a. Clin Cancer Res. 2006 Aug 1;12(15):4645-51. doi: 10.1158/1078-0432.CCR-05-2379. Clin Cancer Res. 2006. PMID: 16899614 Clinical Trial.
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
de Lima Lopes G Jr, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. de Lima Lopes G Jr, et al. Among authors: chiappori a. Cancer. 2007 Apr 1;109(7):1413-9. doi: 10.1002/cncr.22522. Cancer. 2007. PMID: 17326096 Free article. Clinical Trial.
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Münster P, et al. Among authors: chiappori a. J Clin Oncol. 2007 May 20;25(15):1979-85. doi: 10.1200/JCO.2006.08.6165. J Clin Oncol. 2007. PMID: 17513804 Clinical Trial.
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Homsi J, et al. Among authors: chiappori aa. Clin Cancer Res. 2007 Oct 1;13(19):5855-61. doi: 10.1158/1078-0432.CCR-06-2821. Clin Cancer Res. 2007. PMID: 17908979 Clinical Trial.
119 results